iDD biotech has received a second milestone payment after its partner, Genmab, started a Phase I/IIa trial of GEN1029.    This potent and innovative combination of two anti-DR5 antibodies was discovered and developed by iDD biotech, who established preclinical proof of concept in solid tumors with unmet medical needs. In March 2015, Genmab signed an agreement to further develop iDD biotech’s DR5-specific antibodies. Genmab developed GEN1029 (HexaBody-DR5/DR5) by introducing an E430G hexa...